Zydus secures DCGI approval for Saroglitazar to treat liver disease
NASH, a progressive disease of the liver, commences with fat accumulation in the liver and may lead to cirrhosis and liver failure. Saroglitazar is claimed to be the
Novartis has announced the commencement of construction on two new radioligand therapy (RLT) manufacturing facilities in the US, in a bid to expand its production and supply chain capabilities in the sector.
Specifically, they identified novel dual inhibitors of plasmepsins IX and X (PMIX and PMX), two proteases that are essential to Plasmodium falciparum, the predominant cause of the most
AL101, Ayala’s lead product candidate, is a potent, selective, injectable small molecule gamma secretase inhibitor (GSI) and was granted Orphan Drug Designation in May 2019 for the treatment
Financial considerations Under the terms of the agreement, AstraZeneca has received a payment of $350m from Atnahs. The Company may also receive future sales-contingent payments of up to